172 related articles for article (PubMed ID: 21664938)
1. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.
Li Y; Xu W; Tang L; Gong M; Zhang J
Peptides; 2011 Jul; 32(7):1408-14. PubMed ID: 21664938
[TBL] [Abstract][Full Text] [Related]
2. Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1.
Li Y; Li X; Zheng X; Tang L; Xu W; Gong M
Peptides; 2011 Jul; 32(7):1400-7. PubMed ID: 21600946
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
Li Y; Zheng X; Tang L; Xu W; Gong M
Peptides; 2011 Jun; 32(6):1303-12. PubMed ID: 21515323
[TBL] [Abstract][Full Text] [Related]
4. Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo.
Cao Z; Li Y; Tang L; Xu W; Liu C; Zhang J; Gong M
Diabetes Res Clin Pract; 2012 Jun; 96(3):362-70. PubMed ID: 22284602
[TBL] [Abstract][Full Text] [Related]
5. Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications.
Yang X; Li Y; Wang Y; Zheng X; Kong W; Meng F; Zhou Z; Liu C; Li Y; Gong M
Mol Pharm; 2014 Nov; 11(11):4092-9. PubMed ID: 25243635
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
[TBL] [Abstract][Full Text] [Related]
7. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.
Zheng X; Li Y; Li X; Tang L; Xu W; Gong M
Diabetes Res Clin Pract; 2011 Sep; 93(3):410-20. PubMed ID: 21641071
[TBL] [Abstract][Full Text] [Related]
8. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
9. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
10. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
[TBL] [Abstract][Full Text] [Related]
11. Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.
Chen W; Zhou Y; Zhang H; Qian H; Huang W; Yang B; Han J; Zhou J; Chi Y; Ni S
Protein Pept Lett; 2012 Feb; 19(2):203-11. PubMed ID: 21838700
[TBL] [Abstract][Full Text] [Related]
12. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
13. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
Larsen PJ; Wulff EM; Gotfredsen CF; Brand CL; Sturis J; Vrang N; Knudsen LB; Lykkegaard K
Diabetes Obes Metab; 2008 Apr; 10(4):301-11. PubMed ID: 18333889
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
[TBL] [Abstract][Full Text] [Related]
15. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
[TBL] [Abstract][Full Text] [Related]
16. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.
Holst JJ
Diabetologia; 2006 Feb; 49(2):253-60. PubMed ID: 16416146
[TBL] [Abstract][Full Text] [Related]
18. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
19. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
20. Developments of glucagon like peptide-1 (GLP-1) and long-acting analogs in clinical and preclinical studies for treatment of type 2 diabetes.
Li Y; Tang L; Gong M
Curr Pharm Biotechnol; 2013; 14(9):835-41. PubMed ID: 24372261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
